Veltek Associates, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Veltek Associates, Inc. (VAI) provides innovative solutions to address the control of particulate and microbial contamination in pharmaceutical and biotechnology operations worldwide.  We focus on the identification and control of contamination in classified areas.

VAI’s Sterile Chemical Manufacturing Division (SCMD) produces a complete range of sterile disinfectants, sanitizers, sporicides, lubricants, cleaners, detergents (CIP), and buffer solutions.  We offer hand sanitizers and hands-free dispensing systems in addition to developing the Core2Clean Plus System that can spray, mop or fog in one device.   

VAI’s Environmental Control Monitoring Division (ECMD) designs an assortment of viable air sampling equipment.  This product line includes portable devices, compressed air sampling, and facility wide monitoring systems with numerous possibilities to maximize the use of EM information.

VAI’s Disposable Products Manufacturing Division (DPMD) offers sterile cleanroom garments, face masks and nylon packaging material.  These garments also come in a patented fold (Easy2Gown) that makes gowning simple and easy for your operators.



VAI Labs provides microbiological testing ranging from the identification of microorganisms to antimicrobial effectiveness studies, a disinfectant validation service. 

Aseptic Processing Inc. (consulting) provides consulting services in aseptic technique, environmental monitoring, component entry systems, personnel gowning, cleaning and disinfecting systems, and media fill trials.

Veltek Associates, Inc.
www.sterile.com
vai@sterile.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here